All In Biotech

Drug Trial Radar · NCT06703021

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

A Phase 2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Efficacy of Increasing Optimal Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) With at Least One Weight-related Comorbidity (ACCESS II)

Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Dec 20, 2024

Primary completion

Jan 12, 2026

Study completion Jan 12, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1 weight-related comorbidity, in addition to diet and exercise, over a 44-week period.

Conditions

  • Obesity
  • Overweight
  • Chronic Weight Management

Interventions

  • aleniglipron or placeboDrug

    Drug: aleniglipron administered orally; Drug: placebo administered orally

  • aleniglipron or placeboDrug

    Drug: aleniglipron administered orally; Drug: placebo administered orally

  • aleniglipron or placeboDrug

    Drug: aleniglipron administered orally; Drug: placebo administered orally

  • aleniglipron or placeboDrug

    Drug: aleniglipron administered orally; Drug: placebo administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Baseline and week 44
  2. Adverse events of special interestTime frame: Baseline and week 44
  3. Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters, including hematology, plasma chemistry, coagulation, and urinalysisTime frame: Baseline and week 44
  4. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to : heart rate and QRS durationTime frame: Baseline and week 44
  5. Number of Participants With Clinically Significant Change From Baseline in Vital Signs, including systolic and diastolic Blood Pressure, Heart Rate, Respiratory Rate, and temperatureTime frame: Baseline and week 44

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • ACCESS II Research Site

    Glendale, California

  • ACCESS II Research Site

    Montclair, California

  • ACCESS II Research Site

    Valparaiso, Indiana

  • ACCESS II Research Site

    West Des Moines, Iowa

  • ACCESS II Research Site

    Medford, Oregon

  • ACCESS II Research Site

    East Greenwich, Rhode Island

  • ACCESS II Research Site

    North Charleston, South Carolina

  • ACCESS II Research Site

    Dallas, Texas

  • ACCESS II Research Site

    San Antonio, Texas

  • ACCESS II Research Site

    West Jordan, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.